BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 532 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $4,065,225 | +8.5% | 56,737 | +6.6% | 0.02% | +6.2% |
Q1 2024 | $3,748,027 | +4.7% | 53,246 | +14.8% | 0.02% | 0.0% |
Q4 2023 | $3,580,266 | -39.5% | 46,401 | -46.6% | 0.02% | -48.4% |
Q3 2023 | $5,917,372 | +221773.7% | 86,931 | +163.5% | 0.03% | +47.6% |
Q4 2022 | $2,667 | -99.9% | 32,986 | +320.0% | 0.02% | +10.5% |
Q3 2022 | $2,229,000 | -18.9% | 7,854 | +0.1% | 0.02% | -17.4% |
Q2 2022 | $2,749,000 | -17.0% | 7,849 | +0.6% | 0.02% | -4.2% |
Q1 2022 | $3,312,000 | -5.1% | 7,800 | -17.7% | 0.02% | -7.7% |
Q4 2021 | $3,489,000 | -25.7% | 9,480 | +2.1% | 0.03% | -7.1% |
Q3 2021 | $4,693,000 | -58.7% | 9,289 | -61.1% | 0.03% | -58.8% |
Q2 2021 | $11,371,000 | +21.4% | 23,895 | +10.3% | 0.07% | +21.4% |
Q1 2021 | $9,369,000 | -24.3% | 21,664 | -37.6% | 0.06% | -29.1% |
Q4 2020 | $12,379,000 | +3.5% | 34,714 | -22.1% | 0.08% | -9.2% |
Q3 2020 | $11,960,000 | +46.2% | 44,552 | +50.3% | 0.09% | +38.1% |
Q2 2020 | $8,181,000 | +16.0% | 29,650 | -15.1% | 0.06% | -3.1% |
Q1 2020 | $7,052,000 | +0.7% | 34,939 | +6.3% | 0.06% | +22.6% |
Q4 2019 | $7,000,000 | +5.7% | 32,865 | +0.0% | 0.05% | +1.9% |
Q3 2019 | $6,624,000 | +11.2% | 32,850 | +15.8% | 0.05% | +8.3% |
Q2 2019 | $5,957,000 | -4.9% | 28,361 | -7.9% | 0.05% | -5.9% |
Q1 2019 | $6,266,000 | +22.3% | 30,806 | -1.1% | 0.05% | +15.9% |
Q4 2018 | $5,125,000 | -2.7% | 31,147 | +8.4% | 0.04% | +4.8% |
Q3 2018 | $5,268,000 | +3.8% | 28,731 | -13.7% | 0.04% | +20.0% |
Q2 2018 | $5,075,000 | -3.4% | 33,284 | -3.6% | 0.04% | -7.9% |
Q1 2018 | $5,253,000 | +12.8% | 34,513 | +4.8% | 0.04% | +22.6% |
Q4 2017 | $4,656,000 | +21.3% | 32,935 | +6.1% | 0.03% | +10.7% |
Q3 2017 | $3,839,000 | +10.1% | 31,052 | +5.2% | 0.03% | +7.7% |
Q2 2017 | $3,487,000 | +11.7% | 29,515 | +0.8% | 0.03% | +8.3% |
Q1 2017 | $3,122,000 | +9.3% | 29,282 | +4.0% | 0.02% | +4.3% |
Q4 2016 | $2,856,000 | -3.4% | 28,168 | +6.0% | 0.02% | -8.0% |
Q3 2016 | $2,955,000 | +0.9% | 26,585 | +1.0% | 0.02% | 0.0% |
Q2 2016 | $2,928,000 | +22.7% | 26,316 | +2.5% | 0.02% | +19.0% |
Q1 2016 | $2,386,000 | +4.7% | 25,677 | -3.4% | 0.02% | -4.5% |
Q4 2015 | $2,278,000 | -15.4% | 26,568 | -8.8% | 0.02% | -15.4% |
Q3 2015 | $2,693,000 | -77.0% | 29,131 | -75.5% | 0.03% | -48.0% |
Q2 2015 | $11,730,000 | +126.3% | 119,116 | +130.4% | 0.05% | +13.6% |
Q1 2015 | $5,184,000 | – | 51,691 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |